Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | The challenges with implementing CAR-T into the AML treatment landscape

Pietro Genovese • 19 Feb 2024
CAR-T Meeting 2024
Acute Myeloid Leukemia Leukemia CAR-T

In this video, Pietro Genovese, PhD, Harvard Medical School, Boston, MA, comments on whether CAR T-cell therapy could be implemented into the treatment landscape of acute myeloid leukemia (AML) in the future, and discusses some challenges that must be overcome. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pietro Genovese

2:29
Epitope editing enables the use of novel immunotherapies for AML
Pietro Genovese • 19 Feb 2024

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals